Meaningful Use Workgroup Meaningful Use Stage 3 Recommendations

1. Meaningful Use Workgroup Meaningful Use Stage 3 Recommendations Paul Tang, chair George Hripcsak, co-chair

2. Meaningful Use Workgroup Membership • Paul Tang, Chair, Palo Alto Medical Center • George Hripcsak, Co-Chair, Columbia University • David Bates, Brigham & Women’s Hospital* • Christine Bechtel, National Partnership for Women & Families * • Neil Calman, The Institute for Family Health • Tim Cromwell, Department of Veterans Affairs • Art Davidson , Denver Public Health Department * • Paul Egerman, Software Entrepreneur • Marty Fattig, Nemaha County Hospital (NCHNET) • Joe Francis, MD, Veterans Administration • Leslie Kelly Hall, Healthwise • David Lansky, Pacific Business Group on Health • Deven McGraw, Center for Democracy & Technology • Marc Overhage, Siemens Healthcare • Greg Pace, Social Security Administration • Marty Rice, HRSA • Robert Tagalicod, CMS/HHS • Charlene Underwood, Siemens * • Michael H. Zaroukian, Sparrow Health System • Amy Zimmerman, Rhode Island Department of Health and Human Services * Subgroup Leads

3. Stages of Meaningful UseImproving Outcomes Stage 3 2016-17 Stage 2 2014-15 Stage 1 2011-13

4. Original Principles for Stage 3 Recommendations • Supports new model of care (e.g., team-based, outcomes-oriented, population management) • Addresses national health priorities (e.g., NQS, prevention, Partnerships for Patients, Million Hearts) • Broad applicability (since MU is a floor) • Provider specialties (e.g., primary care, specialty care) • Patient health needs • Areas of the country • Not "topped out" or not already driven by market forces • Mature standards widely adopted or could be widely adopted by 2016 (for stage 3)

5. Lessons from Stages 1Implications for Stage 3 Stage 1 Experience • Substantial increase in adoption rates and effective use • Mandatory floor creating network effects • Thresholds consistently exceeded • Consistent use across the years • Reporting requirements have considerable costs and burden • Prescriptive, “forced march” impacts available resources for innovation or to address local priorities Implications for Stage 3 • Creating critical mass of users and data in electronic form • Rising tide is floating boats (e.g., setup for patient engagement, HIE) • Once MU functionality is implemented, it is used • Gains from stage 1 (and 2) will persist • Stage 3: Simplify and reduce reporting requirements • Stage 3: Rely more heavily on market pull (e.g., new payment incentives); promote innovative approaches i.e., reward good behavior

6. Additional Goals for Stage 3 • Address key gaps (e.g., interoperability, patient engagement, reducing disparities) in EHR functionality that the market will not drive alone, but are essential for all providers: • to create level playing field • to create network effects • to fulfill need for a public good • Consider alternative pathway where meeting performance and/or improvement thresholds deems satisfaction of subset of relevant MU functionality implicitly required to achieve performance/improvement • Consolidate MU objectives where higher level objective implies compliance with subsumed process objectives

7. Deeming Pathway

8. Deeming Assumptions • Cannot reliably achieve good performance (or significantly improve) without effective use of HIT • Therefore: in order to promote innovation, reduce burden, and reward good performance, deemhigh performers (or significant improvers) in satisfaction of a subset of MU objectives as an optionalpathwayto qualifying for MU

9. Example Criteria for Deeming for EPs • Demonstrate high (top 30 %ile) or improved performance (20% reduction of gap between last year's performance and top quartile). Select two items from each of the categories below: • Prevention of high priority diseases (pick 2 from) • Breast cancer (mammography screening) • Colon cancer (colonoscopy screening) • Influenza (flu vax) • Pneumonia (pneumococcal vaccine) • Obesity (BMI screening and follow up) • Cardiovascular disease (LDL screen) • HTN (BP screen and follow up) • Control of high priority chronic health conditions (pick 2 from) • HTN (BP control or improvement) • Diabetes (A1c control) • Heart attack (LDL control) • Asthma (controller med) • CHF (ACEI or ARB meds) • MI (beta blocker)

10. Example Criteria for Deeming for EHs • Demonstrate high (top 30 %ile) or improved performance (20% reduction of gap between last year's performance and top quartile) for all of the below: • Patient safety (pick 2 from) • Clostridium difficile Infection (outcome measure) • Catheter-Associated Urinary Tract Infection (outcome measure) • Central Line-Associated Blood Stream Infection (outcome measure) • MRSA (outcome measure) • Specific Surgical Site Infection (SSI) Outcome Measure • Severe sepsis and septic shock: Management bundle • Late sepsis or meningitis in very low birth weight (VLBW) neonates (risk-adjusted) • Measure of pressure ulcers • Care coordination (pick 2 from) • Experience of care (from HCAHPS)? • Hospital-wide-all-cause unplanned readmission measure (HWR) • CTM-3, 3-item care transition

11. Additional Requirement • Disparities • Stratify all four population reports by disparity variables

12. Deemed MU Objectives Deemed in Satisfaction of: • CDS • Reminders • Electronic notes • Test tracking • Clinical summary • Patient education • Reconcile problems, meds, allergies • *View, download, transmit (VDT), consider adding if stage 2 reports good uptake • *Secure patient messaging, consider adding if stage 2 reports good uptake Remaining Items: • Advance directive • eMAR • Imaging results • EH: provide lab results • Patient generated data • *VDT • *Secure patient messaging • Care summary • Notification of health event • Immunization registry • Electronic lab reporting • Syndromic surveillance • Reporting to registries

13. Additional Considerations • Propose performance reporting period to be 6 months vs. 1-year MU reporting period to give providers a chance to deem yet still have time to resort to functional objectives if not meeting deeming thresholds • Specialists may have fewer options for deeming as determined by available NQF QMs.  If not able to report on at least 4 performance measures, then may not be eligible for the deeming pathway

14. Consolidation Work

15. Consolidation Summary • 43 objectives, consolidated to 25 • Assumptions • The full WG will consider RFC feedback and update criteria • All criteria will be included in certification • Focus on advanced uses (e.g. recording data vs. use data) • Give credit for objectives that should be standard of practice after stages 1 and 2

16. Types of Consolidation • Advanced within concept of another objective • Duplicative concepts • objective becomes certification only • Demonstrated use and can trust that it will continue

17. Advanced within Concept of Another Objective Demographics Added as an additional element Patient education, per patient preference Patient preferred means of communication (SGRP208) Reminders, per patient preference Clinical Summary, per patient preference Key: Maintained Objective Certification Criteria

18. Duplicative Concepts CDS (113) Interventions include preventative care for immunizations Immunization intervention (SGRP401B) Included in care summary (303) Structured lab results (SGRP114) Included in view, download, transmit (204A) Key: Maintained Objective Certification Criteria

19. Demonstrated Use • Patient lists and dashboards (SGRP115) • Needed for population management and quality measurement • How to measure use? • Existing external drivers that will drive use (new models of care)

20. CPOE - Advanced within concept of another objective, duplicative concept, demonstrated use Needed to provide meds within care summary (303) CPOE for Medication Orders Needed to provide meds within VDT (204A) Key: Maintained Objective Certification Criteria

21. Consolidation Overview Quality, safety, reducing health disparities Engaging patients & families Improving care coordination Population & public health eRx Order tracking VDT Immunization registry ToC – Care summary Amendment CPOE - referrals ELR Advanced directive CPOE Referral loop CDS Electronic notes ABBI Case reports to PHA CDS for immun Pt list/dashboard Patient education Reconciliation Synd Surveillance CDS for lists Comm preference Demographics Notify of health event Registries Reminders Smoking Cancer registry Care plan Clinical summary Comm preference Specialty registry Inter prob list Vitals Comm preference HAI reports EH: eMAR RxHx PDMP Secure Messaging Imaging results Adverse event PGHD EH: Lab results EP Clinical trials Family Hx Key: Maintained Objective Certification Criteria Changed after consolidation work Future Stage

22. Subgroup 1: Improving quality, safety, efficiency and reducing health disparities David Bates, Subgroup Lead George Hripcsak, MU WG Co-Chair

23. SGRP112: Advance Directive

24. SGRP113: Clinical Decision Support

25. SGRP116: Reminders

26. SGRP117: eMAR

27. Imaging - 118

28. Family History - 119

29. Electronic Notes - 120

30. Hospital Labs - 121

31. Order Tracking - 122

32. UDI - 123 Stage

33. CPOE - 101 Certification ONLY

34. SGRP103: ePrescribing Certification ONLY

35. Demographics – SGRP104 Certification ONLY

36. Problem List- 105 Certification ONLY

37. Medication List - 106 Certification ONLY

38. Med Allergy

39. Vitals – 108 Certification ONLY

40. Smoking - 109 Certification ONLY

41. Lab results - 114 Certification ONLY

42. Patient List -115 Certification ONLY

43. CPOE Referrals - 130 Certification ONLY

44. Subgroup 2 - Engaging Patients and Families Christine Bechtel, Subgroup Lead Paul Tang, MU WG Chair

45. Subgroup 2 • Review of Objectives for full workgroup discussion • Review view, download, transmit (VDT) – 204A • Amendment – 204D • Review patient generated health data (PGHD) – 204B • Review clinical summary/AVS – 205 • Review patient education - 206 • Review secure messaging - 207 • Review communication preferences – 208 • Clinical trial query – 209

46. VDT - 204 A (I)

47. Amendments - 204 D (I)Consolidated with VDT

48. PGHD – 204B

49. Clinical Summary/AVS - 205

50. Patient Education - 206 (I)